Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.
What are Patient Reported Outcomes and why are they important to patients? Patient reported outcomes (PROs) can be thought of as any report or...
The research team at Tulane University is conducting an online survey of individuals with cancer. GRACE has been asked to share information about an...
The research team at Tulane University is conducting an online survey of individuals with cancer. GRACE has been asked to share information about an...
The research team at Tulane University is conducting an online survey of individuals with cancer. GRACE has been asked to share information about an...
The research team at Tulane University is conducting an online survey of individuals with cancer. GRACE has been asked to share information about an...
Transcript
Transcript
Transcript
What is the role for the neuroprotective agent memantine in patients receiving whole brain radiation therapy for brain metastases? Dr. Vivek Mehta reviews current practices to minimize risk of cognitive problems.
Please feel free to offer comments and raise questions in our Discussion Forums.
Transcript
Please feel free to offer comments and raise questions in our Discussion Forums.
Transcript
Liquid biopsies (also called serum testing) is a practice already approved in Europe for EGFR lung cancer patients. Drawing blood to test for acquired resistance is easier and quicker than needle biopsies. How long until it is standard practice in the US?
[powerpress]
A study released at ASCO 2015 showed that the BRAF V600E mutation had a high response rate to combination therapy Tafinlar (dabrafenib) plus Mekinist (trametinib), which led the doctors to agree that BRAF testing in lung cancer should become commonplace.
[powerpress]
Please feel free to offer comments and raise questions in our Discussion Forums.
Transcript
A French study presented at ASCO 2015 showed a survival benefit with Avastin (bevacizumab) added to standard chemo, unlike a prior US study. The doctors discuss the influence of this trial and future potential benefits from immunotherapy in mesothelioma.
[powerpress]
Surgery, specifically a lobectomy or possibly pneumonectomy, has been the longtime historical standard of care for fit patients with early-stage, operable non-small cell lung cancer (NSCLC).
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.